There has been a delay in a batch of ezetimibe with simvastatin (tab 10 mg with simvastatin 10 mg) into the country. As a result, there will be limited supply of this presentation of ezetimibe with simvastatin.
This stock issue is only affecting the 10mg/10mg presentation of ezetimibe with simvastatin.
PHARMAC has received clinical advice that says an alternative of ezetimibe 10 mg with simvastatin 20 mg, or simvastatin alone may be clinically appropriate. GPs who may be considering this presentation for their patients will need to prescribe a
different strength or a different treatment. Patients already using this presentation will need a new prescription for another strength before they can get their medication. GPs may wish to review their patient’s treatment plan and consider whether simvastatin alone or an alternative presentation of ezetimibe with simvastatin would be appropriate.
The other presentations, as below, are still available:
Ezetimibe with simvastatin
o Tab 10 mg with simvastatin 20 mg
o Tab 10 mg with simvastatin 40 mg
o Tab 10 mg with simvastatin 80 mg
It is expected that stock of this presentation of ezetimibe with simvastatin (tab 10 mg with simvastatin 10 mg) will be back to normal in February 2017. Please note the Special Authority number for the combination treatment of ezetimibe with
simvastatin does not extend to approval for ezetimibe by itself. Prescribers will need to complete a Special Authority waiver for ezetimibe for PHARMAC to approve before patients can be dispensed ezetimibe.
More information can be found on the PHARMAC website
If you have any questions, please contact email@example.com or call 0800 660 050.